After an average 44% price cuts, Chinese government will add some blockbuster foreign meds like Celgene's Revlimid to its national insurance scheme.

A whistleblower suit against Gilead is revived, Biocon and Mylan's Herceptin biosim is delayed, and AZ is upping production to meet demands in China.

AstraZeneca is investing $77 million to expand asthma drug production at its Sydney plant, citing rising demand from China.

GlaxoSmithKline is nearing completion of its new manufacturing plant in India that will be able to crank out 8 billion tablets and 1 billion capsules a year.

Mylan and Biocon have hit a stumbling block that will delay potential approval of their biosimilar of Roche’s Herceptin in Europe.

Celgene buys Beigene’s PD-1 inhibitor, Fosun stumbles over rumors about its chairman, Neopharma expands in Japan and Abu Dhabi, and more.

It's the second time in two years that rumors about Fosun Chairman Guo Guangchang's whereabouts stirred the market.

UAE-based Neopharma plans to build a $100 million plant in Abu Dhabi after recently picking up a plant in Japan.

Takeda seeks delay of Velcade copy approvals, a new bid for Sinovac appears, Samsung and Biogen's Humira copycat gets EMA support.

Pharma Asia